Mammalian Cell Culture Global Market Report 2025

The mammalian cell culture market size has grown rapidly in recent years. It will grow from $4.37 billion in 2024 to $4.86 billion in 2025 at a compound annual growth rate (CAGR) of 11.2%. Growth during the historic period can be attributed to the increasing production of monoclonal antibodies, the rising use of CHO and HEK293 cell lines, growing demand for vaccines, expansion of academic and research laboratory activities, and the increasing prevalence of autoimmune and genetic disorders.

The mammalian cell culture market size is expected to see rapid growth in the next few years. It will grow to $7.35 billion in 2029 at a compound annual growth rate (CAGR) of 10.9%. Growth in the forecast period can be attributed to a stronger focus on scalable mammalian cell culture systems, greater adoption of cell-based therapies, rising investment in clinical trials, expansion of biopharmaceutical manufacturing capabilities, and increasing demand for recombinant proteins. Major trends expected in the forecast period include technological advancements in 3D cell culture, innovations in bioprocess optimization, progress in cell line development, advancements in automation and high-throughput screening, and innovations in contamination control and quality assurance.

The increasing demand for personalized medicine is expected to drive the growth of the mammalian cell culture market in the coming years. Personalized medicine tailors medical treatment based on a patient’s genetic, environmental, and lifestyle factors to provide more effective and precise care. The rise in demand for personalized medicine is driven by its ability to improve treatment outcomes by customizing therapies to an individual’s genetic and biological profile. Mammalian cell culture plays a key role in personalized medicine by providing a controlled environment to study patient-specific cells, enabling the development of tailored therapies and testing drug responses for more accurate and effective treatments. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 new personalized treatments for patients with rare diseases in 2023, a significant increase from the six approved in 2022. As a result, the increasing demand for personalized medicine is fueling the growth of the mammalian cell culture market.

Leading companies in the mammalian cell culture market are focusing on innovation in cell culture media, such as two-part production systems, to improve protein yield, enhance cell viability, and streamline scalable bioprocess workflows for therapeutic applications. A two-part production system is a cell culture method that uses two distinct media components: one to support general cell growth and the other to boost protein expression, improving overall productivity. For example, in July 2023, Lonza Group Ltd., a Switzerland-based contract development and manufacturing organization (CDMO), launched the TheraPRO CHO Media System. This chemically defined, animal-component-free media system is designed specifically for GS-CHO mammalian cell lines. It aims to enhance the production of therapeutic proteins and monoclonal antibodies by improving cell viability and protein yields. Its scalable design supports all stages of bioprocess manufacturing, from cell line development to large-scale production. With this launch, Lonza seeks to streamline workflows, improve product quality, and accelerate time-to-market for biopharmaceutical manufacturers.

In December 2024, Merck KGaA, a Germany-based science and technology company, acquired HUB Organoids Holding B.V. for an undisclosed amount. This acquisition aims to advance Merck's next-generation biology portfolio by integrating HUB’s organoid technology to accelerate drug discovery, expand 3D cell-culture capabilities, and provide human-relevant models for disease modeling and toxicity testing. HUB Organoids Holding B.V., based in the Netherlands, specializes in mammalian cell culture-based organoid models that replicate human organ structure and function for research and therapeutic applications.

Major companies operating in the mammalian cell culture market are Novartis AG, Thermo Fisher Scientific Inc., Merck KGaA, Danaher Corporation, GE Healthcare, Becton Dickinson and Company, Lonza Group AG, Avantor Inc., Agilent Technologies Inc., Charles river laboratories, Sartorius AG, Samsung biologics, Wuxi biologics, Bio-Techne Corporation, Miltenyi Biotec, STEMCELL Technologies, Takara Bio Inc., Goodwin biotechnology, HiMedia Laboratories Private Limited, Promocell GmbH, Eppendorf AG, Cell Culture Company LLC, Cell X Technologies.

North America was the largest region in the mammalian cell culture market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in mammalian cell culture report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the mammalian cell culture market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The mammalian cell culture market research report is one of a series of new reports that provides mammalian cell culture market statistics, including the mammalian cell culture industry global market size, regional shares, competitors with the mammalian cell culture market share, detailed mammalian cell culture market segments, market trends, and opportunities, and any further data you may need to thrive in the mammalian cell culture industry. This mammalian cell culture market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Mammalian cell culture is the process of growing animal cells under controlled laboratory conditions outside their natural environment. It involves maintaining cells in a nutrient-rich medium that supplies essential growth factors, gases, and conditions such as temperature and pH. This technique is widely used in research, biotechnology, and medicine for studying cell biology, producing vaccines, and testing drugs. It enables scientists to simulate in vivo conditions and observe cellular behavior in a controlled setting.

The main products used in mammalian cell culture include media, sera, reagents, and equipment. Media refers to nutrient-rich formulations designed to support the growth, proliferation, and maintenance of mammalian cells under controlled laboratory conditions. Key cell lines include Chinese hamster ovary (CHO), Wistar Institute-38 (WI-38), rat glial tumor cell line (C6), human embryonic kidney 293 (HEK293), and Henrietta Lacks (HeLa). Major applications span biopharmaceutical production, vaccine production, toxicity testing, drug screening and development, and tissue engineering and regenerative medicine, with primary end users including pharmaceutical and biotechnology companies, hospitals and diagnostic laboratories, research and academic institutes, and contract research organizations (CROs).

The mammalian cell culture market consists of sales of media, sera, reagents, equipment, bioreactors, culture plates, flasks, incubators, centrifuges, and microscopes. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.